Highlights include a 2024 Best of ASCO® oral abstract on
unrelated donor blood stem cell transplantation, late-breaking oral
abstract on combination sotorasib for patients with a
treatment-resistant tumor mutation called KRAS G12C, and
monotherapies for people with advanced cancers
World-renowned physicians and researchers from City of Hope®,
one of the largest cancer research and treatment organizations in
the United States, will present new data and offer expert
perspectives on leading-edge cancer research and treatments in
development at the 2024 ASCO Annual Meeting, which will take place
in Chicago from May 31 to June 4. Highlights include the
following:
- 2024 Best of ASCO® program: New data on mismatched
unrelated donor peripheral blood stem cell transplantation
- Late-breaking data on the phase 3 CodeBreaK 300 trial
- Glofitamab monotherapy for patients with advanced mantle cell
lymphoma
- An oral inhibitor monotherapy for people with advanced kidney
cancer
- Interventions for older adults with cancer who traditionally
have not had access to supportive care treatments that could
improve quality of life
About 40,000 oncology professionals will attend the meeting,
themed “The Art and Science of Cancer Care: From Comfort to Cure.”
City of Hope experts will have 64 presentations, including oral
sessions, clinical science symposiums, education discussions and
the following late-breaking abstract:
Overall survival (OS) of phase 3 CodeBreaK
300 study of sotorasib plus panitumumab (soto+pani) versus
investigator’s choice of therapy for KRAS G12C-mutated metastatic
colorectal cancer (mCRC)
- Presenter: Marwan G. Fakih, M.D., City of Hope medical
oncologist
- Presentation Time and Location: Monday, June 3, 1:21 p.m. CT,
Arie Crown Theater
Other noteworthy City of Hope abstracts:
Expanding access to stem cell transplants: Not a perfect
match, yet perhaps just as good Presentation Time and Location:
Friday, May 31, 3:45 p.m. CT, S100bc
Access to potentially lifesaving stem cell transplants
traditionally has been limited due to the need for a donor whose
stem cells match the recipient’s genes. However, Monzr M. Al Malki,
M.D., City of Hope hematologist-oncologist, co-led a multicenter
phase 2 trial (NCT04904588) sponsored by NMDP and conducted via
CIBMTR (Center for International Blood and Marrow Transplant
Research) that demonstrates encouraging overall survival one year
after older patients with advanced blood cancers received
“HLA-mismatched unrelated donor peripheral blood stem cell
transplantation,” meaning the donor stem cells originated from
someone who was not a relative and not a complete HLA match.
While the 13-site ongoing trial includes adults and children,
this interim analysis that will be presented as an oral abstract
presentation evaluated the first 70 older adult patients with
advanced blood cancers who received this type of transplant and
underwent both reduced intensity conditioning and post-transplant
cyclophosphamide, which is a method used to prevent a potentially
life-threatening side effect called graft-versus-host disease
(GVHD). City of Hope has performed over 19,000 transplants, is one
of the nation’s leading transplant programs and is at the forefront
of using transplants to treat older adults with blood cancers.
Overall survival at one year post-stem cell transplant was 79%.
Rates of GVHD and other complications were comparable to those of
recipients who received HLA-matched donor stem cells, suggesting
HLA-mismatched unrelated donor peripheral blood stem cell
transplantation may one day be used more widely, expanding access
to the lifesaving therapy.
“This data, supported by the National Marrow Donor Program, is
promising and is the reason why I continue to work to expand access
to stem cell transplantation for older patients, underrepresented
people and patients with blood cancers,” Dr. Al Malki said.
The adult cohorts of this trial recruitment have closed with
more than 200 patients in follow-up. The pediatric arm of the trial
is ongoing.
Bispecific antibody demonstrates sustained response rates in
lymphoma patients who received and rejected previous treatments
Presentation Time and Location: Saturday, June 1, 5:24 p.m. CT,
S100bc
In an updated efficacy and safety phase 1/2 trial (NCT03075696),
bispecific antibody glofitamab continues to demonstrate compelling
response rates with a fixed-duration treatment among a group of
mantle cell lymphoma patients who have nearly exhausted approved
treatment options due to aggressive disease.
The researchers evaluated close to 60 participants who had
received two or more previous treatments — the majority of which
had stopped responding to treatment before they enrolled in this
study. Patients received about 7.4 months of glofitamab. Landmark
analyses indicated that most patients with a complete response at
the end of treatment were alive without disease progression 15
months after the end of treatment. The median duration of complete
response was 12.6 months, and median progression-free survival was
8.6 months.
“People with mantle cell lymphoma have a rare form of
non-Hodgkin lymphoma that is currently incurable, so it is
encouraging to see people who were told by others that there is not
much more to be done live months and even years longer with this
treatment,” said Tycel Phillips, M.D., City of Hope
hematologist-oncologist and presenting author. “We at City of Hope
continuously develop leading-edge treatments for people diagnosed
with lymphoma and other blood cancers.”
Early safety and clinical efficacy data on monotherapy DFF332
in advanced kidney cancer patients Presentation Time and
Location: Saturday, June 1, from 8:30 a.m. CT, S100bc
People with an advanced kidney cancer called clear cell renal
cell carcinoma (ccRCC) appeared to experience positive medicinal
effects from the targeted therapy pill DFF332 while encountering
manageable side effects in an ongoing first-in-human phase 1/1B
multicenter trial (CDFF332A12101, NCT04895748).
Sumanta “Monty” Pal, M.D., a City of Hope medical oncologist,
will share preliminary data on 40 advanced kidney cancer patients
who took DFF332, an oral hypoxia-inducible factor (HIF)-2α
inhibitor that has been shown in preclinical models to be effective
in reducing ccRCC tumors. All study participants had received at
least one other type of therapy before joining the clinical trial.
At data cutoff, 16 patients continued to be treated, while 19
patients (48%) stopped receiving the treatment due to disease
progression. The most common side effects were fatigue (33%),
anemia (30%), increased blood cholesterol and constipation (15%).
No extreme adverse effects have been observed so far. At cutoff, 18
patients (45%) had stable disease and two patients (5%) achieved
partial response.
“While the study is still in process, so far, we have seen a
promising safety profile for monotherapy DFF332 with indications of
clinical activity,” Dr. Pal said. “We are conducting analysis on
how the medicine moves within the body as well as collecting
biomarker data that will be shared at our ASCO presentation.”
Using telehealth to improve access to supportive care
services for older adults with cancer living in lower-resourced
communities Presentation Time and Location: Saturday, June 1,
at 1:39 p.m. CT, S102
A study at City of Hope | Antelope Valley found that telehealth
can be leveraged to offer older adults living in high-poverty,
lower resourced communities with a specialized evaluation developed
at City of Hope called a geriatric assessment, which identifies
supportive care services older adults with cancer need to manage
vulnerabilities, better define care goals and improve quality of
life.
This quality improvement study included 251 participants who
were 65 years or older with newly diagnosed or advanced cancer.
These patients underwent a baseline geriatric assessment and most
had initial visits with a geriatric nurse practitioner – 197 via
televideo and 45 via telephone. The assessment identified
vulnerabilities in 209 patients and, after review, the nurse
practitioner made 460 necessary referrals for supportive care
services – 86% of which were implemented. The most common referrals
were to pharmacy (177), social work (142), occupational therapy
(76) and physical therapy (48). More than 92% of patients reported
they were satisfied with the telehealth services that resulted in
supportive care interventions for older adults.
“In my experience, if you don’t do a geriatric assessment, the
patient pays for it later,” said Tanyanika Phillips, M.D., M.P.H.,
presenting author and City of Hope medical oncologist and
hematologist in Antelope Valley, California. Phillips noted that if
care is prescribed without accurate health information, the result
could be serious side effects or even hospitalization, which could
lead not only to more costly care but also cancer treatment
outcomes that are not the best for patients.
“In a general visit, patients often will say they feel well and
are fine because they’re incentivized to answer in the affirmative
and move forward with treatment," Phillips added. “Place this same
patient in a different environment where they are answering
geriatric assessment questions, and they may be more forthcoming
and detailed about their lifestyle and abilities. This candor will
help physicians prescribe the most appropriate care for that
individual based on their circumstances.”
Providing supportive care interventions via telehealth based
on a geriatric assessment is shown to improve daily functioning,
happiness and quality of life Presentation Time and Location:
Sunday, June 2, from 11:54 a.m. CT, S100bc
A randomized trial at a Brazilian cancer center and under the
guidance of City of Hope’s internationally renowned cancer and
aging expert William Dale, M.D., Ph.D., found that older adults
with metastatic cancer reported experiencing significant
improvements in the performance of daily activities, emotional
well-being and quality of life after receiving a telehealth-based
geriatric assessment (GA) that resulted in supportive care
interventions. This data extends City of Hope’s prior work in
GA-guided supportive care beyond the borders of the United
States.
“Our studies continue to prove that patients and families win
when care teams ask older adults with cancer the right questions at
the outset to guide care. This is true even when telehealth is used
in a low-resource environment. Guidance from a GA can change care
choices and improve outcomes — all without making cancer therapy
less effective. It’s a form of precision medicine: more appropriate
supportive care interventions, better daily functioning, higher
quality of life and the same great cancer care results. It’s a
winning formula for patients, families, providers and the health
system,” said Dr. Dale, senior author of the study, City of Hope’s
George Tsai Family Chair in Geriatric Oncology and director of City
of Hope’s Center for Cancer and Aging. Dr. Dale is the recipient of
this year’s B.J. Kennedy Geriatric Oncology Award, which honors
geriatric oncologists who have demonstrated outstanding leadership
and achievement in the field of geriatric oncology.
Additional highlights include the following award-winning poster
abstract and three education sessions:
- “A phase I/II trial of palbociclib, pembrolizumab, and
endocrine therapy for patients with HR+/HER2- locally advanced or
metastatic breast cancer (MBC): Clinical outcomes and stool
microbial profiling”* Presentation Time: Sunday, June 2, from 9
a.m. to noon CT Presenter: Alexis LeVee, M.D., City of Hope
Hematology & Medical Oncology Chief Fellow *Conquer Cancer, the
ASCO Foundation, awarded Dr. LeVee a 2024 ASCO Annual Meeting Merit
Award, which supports students and trainees who are first authors
on abstracts selected for presentation.
- “Evidence Evaluating Cannabis’ Efficacy Across the Cancer
Care Continuum” Monday, June 3, 8:30 a.m. CT Session title:
Evidence-Based Integrative Oncology: Guideline Insights for
Comprehensive Care Presenter: Richard T. Lee, M.D., City of Hope
clinical professor, Supportive and Integrative Medicine Program;
Cherng Family Director's Chair for the Center for Integrative
Oncology
- “Tissue-Based Molecular Testing and the Role of Artificial
Intelligence” Monday, June 3, 10 a.m. CT Session title: Should
I Order the Test? Expanding the Array of Emerging Diagnostics in
Breast Cancer Presenter: Daniel Schmolze, M.D., City of Hope
associate clinical professor, Department of Pathology
- “What Is Variant Histology Renal Cell Cancer and What Are
the Available Treatment Options?” Monday, June 3, 3:15 p.m. CT
Session title: Managing Variant Histologies in Urothelial and Renal
Cell Cancers Presenter: Sumanta Kumar Pal, M.D., City of Hope
professor, Department of Medical Oncology & Therapeutics
Research
About City of Hope
City of Hope's mission is to make hope a reality for all touched
by cancer and diabetes. Founded in 1913, City of Hope has grown
into one of the largest cancer research and treatment organizations
in the U.S. and one of the leading research centers for diabetes
and other life-threatening illnesses. City of Hope research has
been the basis for numerous breakthrough cancer medicines, as well
as human synthetic insulin and monoclonal antibodies. With an
independent, National Cancer Institute-designated comprehensive
cancer center at its core, City of Hope brings a uniquely
integrated model to patients spanning cancer care, research and
development, academics and training, and innovation initiatives.
City of Hope’s growing national system includes its Los Angeles
campus, a network of clinical care locations across Southern
California, a new cancer center in Orange County, California, and
cancer treatment centers and outpatient facilities in the Atlanta,
Chicago and Phoenix areas. City of Hope’s affiliated group of
organizations includes Translational Genomics Research Institute
and AccessHope™. For more information about City of Hope, follow us
on Facebook, X, YouTube, Instagram and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523991715/en/
Zen Logsdon 626-409-9367 zlogsdon@coh.org